# US 2014/0155582 A1 · Novel anti-human ngf antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155582 A1
- Document ID: US20140155582A1
- Status: Published application
- Kind: A1
- Application number: 13/879,267
- Filed: 2012-08-10
- Published: 2014-06-05
- Earliest claimed: 2011-08-11
- Assignees: Astellas Pharma Inc.
- Inventors: Masazumi Kamohara; Hirotsugu Tanaka; Yukari Koya; Jun Takasaki; Atsuo Yonezawa; Eiji Yoshimi
- Web page: https://patentgrep.com/patent/US20140155582A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

[Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab′ fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.

## Claims

### Claim 1

An anti-human NGF antibody Fab′ fragment comprising:
a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6; and
a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.

### Claim 2 (depends on 1)

The Fab′ fragment according to claim 1, wherein a heavy-chain constant region of the Fab′ fragment is a human Igγ1 constant region.

### Claim 3 (depends on 1)

The Fab′ fragment according to claim 1, wherein a light-chain constant region of the Fab′ fragment is a human Igκ constant region.

### Claim 4 (depends on 1)

The Fab′ fragment according to claim 1, wherein a heavy-chain constant region of the Fab′ fragment is the human Igγ1 constant region, and a light-chain constant region of the Fab′ fragment is the human Igκ constant region.

### Claim 5 (depends on 1)

The Fab′ fragment according to claim 1, comprising:
a heavy-chain fragment consisting of an amino acid sequence shown by SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:16; and
a light chain consisting of an amino acid sequence shown by SEQ ID NO:12.

### Claim 6 (depends on 1)

The Fab′ fragment according to claim 1, wherein the Fab′ fragment is conjugated to polyethylene glycol.

### Claim at position 7

-8. (canceled)

### Claim 9 (depends on 1)

An expression vector comprising a polynucleotide comprising a sequence that encodes a heavy-chain fragment of the Fab′ fragment according to claim 1 and a polynucleotide comprising a sequence that encodes a light chain of the Fab′ fragment.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A host cell, which is selected from the group consisting of:
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain fragment of the Fab′ fragment according to claim 1 and a polynucleotide comprising sequence that encodes the light chain of the Fab′ fragment; and
(b) a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain fragment of the Fab′ fragment according to claim 1 and with an expression vector comprising a polynucleotide comprising a sequence that encodes the light chain of the Fab′ fragment.

### Claim 12 (depends on 11)

A method, comprising:
expressing an anti-human NGF antibody Fab′ fragment by culturing the host cell according to claim 11, thereby producing an anti-human NGF antibody Fab′ fragment that comprises a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.

### Claim 13 (depends on 8)

An expression vector comprising the polynucleotide according to claim 8.

### Claim 14 (depends on 13)

A host cell transformed with the expression vector according to claim 13.

### Claim 15

(canceled)

### Claim 16 (depends on 2)

The Fab′ fragment according to claim 2, wherein the Fab′ fragment is conjugated to polyethylene glycol.

### Claim 17 (depends on 3)

The Fab′ fragment according to claim 3, wherein the Fab′ fragment is conjugated to polyethylene glycol.

### Claim 18 (depends on 4)

The Fab′ fragment according to claim 4, wherein the Fab′ fragment is conjugated to polyethylene glycol.

### Claim 19 (depends on 5)

The Fab′ fragment according to claim 5, wherein the Fab′ fragment is conjugated to polyethylene glycol.